Free Trial
→ Inside the Options Play With a High Historical Win Rate (From TradeWins) (Ad)tc pixel
NASDAQ:COLL

Collegium Pharmaceutical Q3 2026 Earnings Date & Estimates

Collegium Pharmaceutical logo
$22.09 -0.02 (-0.09%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$22.06 -0.03 (-0.14%)
As of 10/9/2026 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Collegium Pharmaceutical is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Collegium Pharmaceutical in Q3 2026

Collegium Pharmaceutical is expected to post earnings of $1.78 per share on revenue of $216.32 million. In the same quarter a year earlier Collegium Pharmaceutical reported $2.25 per share on revenue of $209.36 million. Collegium Pharmaceutical last reported on August 6, 2026, posting $1.92 per share and beating the $1.72 consensus estimate. Collegium Pharmaceutical has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$1.78
Expected Revenue
$216.32 million
Prior-Year EPS
$2.25
Prior-Year Revenue
$209.36 million
Expected EPS Growth
-20.9%
Expected Revenue Growth
+3.3%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$1.92 (Beat by +$0.20)
Last Quarter Revenue
$199.88 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Collegium Pharmaceutical Q3 2026 Earnings FAQ

Collegium Pharmaceutical (NASDAQ:COLL) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens.

Collegium Pharmaceutical's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Collegium Pharmaceutical to post earnings of $1.78 per share for Q3 2026.

The consensus revenue estimate for Collegium Pharmaceutical is $216.32 million for Q3 2026.

Collegium Pharmaceutical Earnings Headlines

Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says
October 9 at 11:59 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/collegium-pharmaceutical-outlook-supported-adhd-173215330.html
Collegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to "Strong Sell" at Zacks Research
October 8 at 6:12 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099354
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
October 10 at 1:00 AM  |  Behind the Markets (Ad)
Collegium Pharmaceutical, Inc. Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
October 6, 2026  |  marketscreener.comM
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375438/34897/en/collegium-launches-start-talking-adhd-with-practical-support-to-help-families-navigate-care-school-and-everyday-life.html
Collegium Pharmaceutical (NASDAQ:COLL) vs. Sanofi (NASDAQ:SNY) Critical Survey
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090786
See More Collegium Pharmaceutical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Collegium Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Collegium Pharmaceutical and other key companies, straight to your email.

About Collegium Pharmaceutical

Collegium Pharmaceutical (NASDAQ:COLL) is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation. The company also markets Jornay PM, an extended-release methylphenidate product for attention-deficit hyperactivity disorder.

Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium primarily serves the U.S. specialty pharmaceutical market. Its growth strategy has included product acquisitions and portfolio expansion, including the acquisition of BioDelivery Sciences International and the purchase of Ironshore Therapeutics, which added Jornay PM to its commercial portfolio.

View Collegium Pharmaceutical Profile
Earnings Tools